Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
- PMID: 17637811
- DOI: 10.1038/sj.leu.2404858
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
Abstract
Peptides from the e14a2 BCR-ABL junction will elicit T-cell responses in vitro. Here, 19 imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides spanning the e14a2 fusion junction, some of which were linked to the pan DR epitope PADRE to augment CD4+ T cell help. Six vaccinations were given over 9 weeks, together with sargramostim. All patients developed mild local reactions. T cell responses to PADRE were seen in all patients. Fourteen of 19 patients developed T cell responses to BCR-ABL peptides. The development of an anti-BCR-ABL T cell response correlated with a subsequent fall in BCR-ABL transcripts. No molecular benefit was seen in the 5 patients not in major cytogenetic response (MCR) at baseline. However, of the 14 patients in MCR at baseline, 13 developed at least 1 log fall in BCR-ABL transcripts, though this occurred several months after completing vaccination, consistent with an effect at a primitive CML stem cell level. Vaccination may improve the fall in BCR-ABL transcripts in patients who have received imatinib for more than 12 months. BCR-ABL peptide vaccination may improve control of CML, especially in patients responding well to imatinib. Randomised trials are required to address this further.
Similar articles
-
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.N Engl J Med. 2003 Oct 9;349(15):1423-32. doi: 10.1056/NEJMoa030513. N Engl J Med. 2003. PMID: 14534335 Clinical Trial.
-
Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.Leuk Res. 2007 Dec;31(12):1675-81. doi: 10.1016/j.leukres.2007.01.007. Epub 2007 Feb 26. Leuk Res. 2007. PMID: 17324459
-
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.Leukemia. 2003 Sep;17(9):1687-94. doi: 10.1038/sj.leu.2403033. Leukemia. 2003. PMID: 12970765
-
[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].Rinsho Byori. 2004 Feb;52(2):136-44. Rinsho Byori. 2004. PMID: 15027317 Review. Japanese.
-
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.Nat Rev Cancer. 2007 May;7(5):345-56. doi: 10.1038/nrc2126. Nat Rev Cancer. 2007. PMID: 17457302 Review.
Cited by
-
BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.Cancer Immunol Immunother. 2009 Sep;58(9):1449-57. doi: 10.1007/s00262-009-0703-x. Epub 2009 Apr 10. Cancer Immunol Immunother. 2009. PMID: 19360407 Free PMC article.
-
Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?Cancer Immunol Immunother. 2009 Sep;58(9):1489-99. doi: 10.1007/s00262-009-0675-x. Epub 2009 Mar 4. Cancer Immunol Immunother. 2009. PMID: 19259670 Free PMC article. Review.
-
DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.Hum Vaccin Immunother. 2016 May 3;12(5):1117-23. doi: 10.1080/21645515.2015.1132965. Epub 2016 Feb 10. Hum Vaccin Immunother. 2016. PMID: 26864050 Free PMC article.
-
Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.PLoS One. 2011;6(8):e23022. doi: 10.1371/journal.pone.0023022. Epub 2011 Aug 9. PLoS One. 2011. PMID: 21857985 Free PMC article.
-
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.Best Pract Res Clin Haematol. 2008 Sep;21(3):437-53. doi: 10.1016/j.beha.2008.07.004. Best Pract Res Clin Haematol. 2008. PMID: 18790448 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
